MULTIDRUG DELIVERY MICROPARTICLE COATINGS FOR ORTHOPEDIC DEVICES

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,505.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
1R43AR052970-01A1
Award Id:
80291
Agency Tracking Number:
AR052970
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
INNOVATIVE SURFACE TECHNOLOGIES, LLC, 1000 WESTGATE DR, STE 260, ST. PAUL, MN, 55114
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PATRICKGUIRE
(651) 209-9757
pguire@isurtec.com
Business Contact:
WAYNEVANDER VORT
(851) 209-9758
WVANDERVORT@ISURTEC.COM
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): The goal of this SBIR project is to develop drug-eluting biocompatible coatings for implantable orthopedic devices. The specific goal for the Phase I effort is the coating of orthopedic material for extended simultaneous delivery of three classes of antimicrobial drugs (antiseptic, antibiotic and microbiocidal polypeptide) from bioabsorbable micro particles combined in a single coating step with photoreactive polymer matrices. Successful demonstration of this new technology will provide the basis for further development for orthopedic implants of biocompatible coatings combining various facets of infection resistance, pain control, and wound healing. The primary innovation will be technology for immobilizing drug-loaded bioabsorbable micro particles on implantable surfaces with photoreactive polymer matrices. Particle compositions suitable for extended delivery of low molecular weight drugs of differing solubilities, and biological macromolecules, at chosen respective elution rates, will be prepared. These drug-loaded particles will be immobilized in a photocrosslinked polymer film which is biocompatible and stable to hold the particles during implantation. This "next generation" technology in drug-eluting medical device coatings will result from the combination of drug-loaded degradable particle technology with latent-reactive polymer immobilization technology. Demonstration of drug-eluting micro particle immobilization in the Phase I effort will provide justification for a Phase II project for optimizing the components of the coating technology and safety and usefulness tests in animals. Key words (8 max): Antimicrobial drug-eluting device coatings, degradable micro particle immobilization Summary of potential commercial applications: Controlled delivery of multiple drugs from implantable medical device coatings is expected to contribute significantly to the drug-eluting implantable device market reaching $5 to 6 billion by 2005, including orthopedic devices, stents, vascular graft catheters and wraps, implanted biosensors, ophthalmic, and cosmetic implants, with a total market potential of greater than $20 billion within 10 years.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government